Percutaneous ablation of hepatocellular carcinoma: State-of-the-art

Lencioni, Riccardo; Cioni, Dania; Crocetti, Laura; Bartolozzi, Carlo

doi:10.1002/lt.20043

Cited by 109 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no standard treatment for unresectable HCC, but transarterial chemoembolization (TACE) has been shown to increase survival in a randomized controlled trial . Percutaneous ethanol injection (PEI) has also proven to be relatively easy to perform and is inexpensive (Lencioni et al, 2004). Retrospective data from one Japanese centre suggests that percutaneous tumour ablation methods can become as efficient as surgical procedures (Omata et al, 2004).…”

mentioning

confidence: 99%

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Greten¹,

Papendorf

Bleck³

et al. 2005

Br J Cancer

176

101

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child -Pugh score B or C) and a score of 42. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.

show abstract

mentioning

confidence: 99%

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Greten¹,

Papendorf

Bleck³

et al. 2005

Br J Cancer

176

101

View full text Add to dashboard Cite

show abstract

“…6 Other advances were also obtained in the monitoring and analysis of the RFA procedure, with the application of fiber optic sensors to perform the online monitoring of the temperature in the region of ablation. 7 The temperature analysis is able to quantify the heat distribution in the ablation region and thereby determine the efficiency of the procedure performed.…”

Section: 4mentioning

confidence: 99%

The use of Radiofrequency for Hepatocellular Carcinoma Ablation: An Update Review and Perspectives

Monteiro¹,

Guimarães²,

Motta³

et al. 2017

IJBSBE

View full text Add to dashboard Cite

The World Health Organization classifies liver cancer among the five types of cancer with highest death rates in the world. Among the current methods available for the treatment of liver cancer, there is the resection of hepatic tissue and the radiofrequency ablation of the tumor. Even though resection presents the best results, only 10% to 15% of the affected patients may eligible for this procedure. On the other hand, the radiofrequency ablation encompasses a larger scope of patients and provides a non-invasive method when compared to resection. There is research with sufficient evidence to allow the transposition of this concept to new technological paradigms, which would yield a more effective ablation process, i.e.: generating enough volumetric necrosis for complete regression of the tumor, leading to a high survival rate of patients. These technological paradigms encompass aspects of operability, innovation and of theoretical framework. In terms of operability, there is the use of better imaging sources to aid the healthcare professional in the positioning of electrodes; in terms of innovation, there are new technologies such as the use of optical fiber microsensors and metallic magnetic nanoparticles to increase the efficiency of the process; in terms of theoretical framework, there is the development of more precise mathematical models that would expand the possibilities of application and increase its effectiveness. These new challenges are new possibilities that may reshape the concept and the use of radiofrequency ablation as it is currently known.

show abstract

“…[1][2][3] RFA enables more effective tumor necrosis in fewer treatment sessions, albeit with a higher rate of complications than does PEI therapy. 1,6,7 Because of its high local recurrence rate, PEI therapy has been replaced by newer and more effective thermal ablation techniques. 6 It is reasonable to reserve PEI therapy for HCCs that are difficult to approach with RFA or located in areas where RFA is considered unsafe.…”

Section: Introductionmentioning

confidence: 99%

Is Percutaneous Ethanol Injection Therapy Still Effective for Hepatocellular Carcinoma in the Era of Radiofrequency Ablation?

Kwon

2010

Gut Liver

View full text Add to dashboard Cite

Percutaneous ethanol injection (PEI) therapy has been replaced by more-effective thermal ablation techniques that have lower local recurrence rates. However, PEI therapy remains useful in certain settings. Since PEI can be performed in any portion of the liver, PEI therapy can be valuable when tumors are located in close proximity to intestinal loops or other positions that are risky for thermal local ablative techniques. PEI therapy is also valuable in other situations where radiofrequency ablation (RFA) is difficult, including technically difficult masses that are not detected with ultrasound (US), are located in the hepatic dome, in the subcapsular area, and exophytically, or are surrounded by large vessels. PEI therapy contributes to combination therapy with transcatheter arterial chemoembolization or RFA in advanced-stage hepatocellular carcinoma (HCC), and also to the treatment of large HCC or extrahepatic metastasis from HCC. These roles of PEI therapy should be stressed for the treatment of HCCs in appropriate clinical situations. This comprehensive review of articles related to PEI therapy illustrates the recent role and indications of this therapy, which is currently valuable for HCC in the era of RFA. (Gut Liver 2010;4(Suppl. 1):S105-112)

show abstract

Percutaneous ablation of hepatocellular carcinoma: State-of-the-art

Cited by 109 publications

References 40 publications

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

The use of Radiofrequency for Hepatocellular Carcinoma Ablation: An Update Review and Perspectives

Is Percutaneous Ethanol Injection Therapy Still Effective for Hepatocellular Carcinoma in the Era of Radiofrequency Ablation?

Contact Info

Product

Resources

About